Acadia shares are down 13% to $20.46 in pre-market trading after the company announced intranasal carbetocin did not demonstrate a statistically significant improvement over placebo on the study’s primary endpoint in the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin in patients with hyperphagia in Prader-Willi syndrome.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Soleno jumps 11% to $63.37 after Acadia trial miss
- Wells sees Soleno’s shares trading up at least 20% on Acadia’s failure in PWS
- Acadia Pharmaceuticals announces COMPASS PWS trial misses endpoints
- Acadia Pharmaceuticals publishes interim LOTUS study data in journal
- Acadia Pharmaceuticals price target raised to $39 from $35 at TD Cowen